Microflora Modulation of Motility = Microflora Modulation of Motility

다국어 초록 (Multilingual Abstract)

That gastrointestinal motility can influence the gut microbiota has been known for decades and the clinical consequences of impaired motility, in terms of the bacterial population of the small intestine, amply illustrated by the syndrome of small intestinal bacterial overgrowth which so commonly accompanies diffuse intestinal motility disorders. As the importance of the microbiota to homeostasis in health and to a variety of disease states is increasingly appreciated and as the full diversity and biology of this "hidden organ" have been revealed by molecular methodologies, the true nature of the interaction between the microbiota and motility is being re-examined and the complexity of this relationship exposed. In health, as well as in disease states, this is a truly bi-directional relationship: not only can gut motor patterns influence the microbiota but changes in the microbiota can exert profound influences on gut sensori-motor function. (J Neurogastroenterol Motil 2011;17:140-147)

참고문헌 (Reference)

1 Qin H, "plantarum prevents enteroinvasive Escherichia coli-induced tight junction proteins changes in intestinal epithelial cells" 9 : 63-, 2009

2 Quigley EM, "Tonic pressures at the canine ileocolonic junction: topography and relationship to phasic motor activity" 249 (249): G350-G357, 1985

3 Vanner S, "The small intestinal bacterial overgrowth. Irritable bowel syndrome hypothesis: implications for treatment" 57 : 1315-1321, 2008

4 Gwee KA, "The role of psychological and biological factors in post-infective gut dysfunction" 44 : 400-406, 1999

5 Quigley EM, "The motor response to intestinal resection: motor activity in the canine small intestine following distal resection" 105 : 791-798, 1993

6 Vanner S, "The lactulose breath test for diagnosing SIBO in IBS patients: another nail in the coffin" 103 : 964-965, 2008

7 Vantrappen G, "The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine" 59 : 1158-1166, 1977

8 Collins SM, "The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders" 11 : 1683-1699, 1996

9 Hattori M, "The human intestinal microbiome: a new frontier of human biology" 16 : 1-12, 2009

10 Kassinen A, "The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects" 133 : 24-33, 2007

11 Pimentel M, "The effect of a nonabsorbed antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial" 145 : 557-563, 2006

12 Wedlake L, "Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome" 30 : 707-717, 2009

13 Thabane M, "Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome" 26 : 535-544, 2007

14 Verdú EF, "Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice" 55 : 182-190, 2006

15 Quigley EM, "Small intestinal motor activity - its role in gut homeostasis in health and disease" 65 : 799-810, 1987

16 Riordan SM, "Small intestinal bacterial overgrowth in the symptomatic elderly" 92 : 47-51, 1997

17 Marie I, "Small intestinal bacterial overgrowth in systemic sclerosis" 48 : 1314-1319, 2009

18 Parodi A, "Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication" 103 : 1257-1262, 2008

19 Quigley EM, "Small intestinal bacterial overgrowth" 24 : 943-959, 2010

20 Ford AC, "Small Intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis" 7 : 1279-1286, 2009

21 Kamath PS, "Short-chain fatty acids stimulate motility of the canine ileum" 253 (253): G427-G433, 1987

22 Kamath PS, "Short-chain fatty acids stimulate ileal motility in humans" 95 : 1496-1502, 1988

23 van der Veek PP, "Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome" 100 : 2510-2516, 2005

24 Spiller RC, "Role of nerves in enteric infection" 51 : 759-762, 2002

25 Cenac N, "Role for protease activity in visceral pain in irritable bowel syndrome" 117 : 636-647, 2007

26 Pimentel M, "Rifaximin therapy for patients with irritable bowel syndrome without constipation" 364 : 22-32, 2011

27 Lembo A, "Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response" 134 (134): A545-, 2008

28 Picard C, "Review article: bifidobacteria as probiotic agents - physiological and clinical effects" 22 : 495-512, 2005

29 Dunlop SP, "Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS" 125 : 1651-1659, 2003

30 Lesniewska V, "Relationship between dietary-induced changes in intestinal commensal microflora and duodenojejunal myoelectric activity monitored by radiotelemetry in the rat in vivo" 91 : 229-237, 2006

31 Spiegel BM, "Questioning the bacterial overgrowth hypothesis of IBS: an epidemiologic and evolutionary perspective" 10 : 2011

32 Thompson JS, "Qualitative changes in enteric flora and short-chain fatty acids after intestinal resection" 43 : 624-631, 1998

33 Asfaha S, "Persistent epithelial dysfunction and bacterial translocation after resolution of intestinal inflammation" 281 : G635-G644, 2001

34 Hassan BB, "Patterns of antropyloric motility in fed healthy preterm infants" 87 : F95-F99, 2002

35 Pimentel M, "Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study" 98 : 412-419, 2003

36 Lamine F, "Nitric oxide released by Lactobacillus farciminis improves TNBS-induced colitis in rats" 39 : 37-45, 2004

37 Swidsinski A, "Mucosal flora in inflammatory bowel disease" 122 : 44-54, 2002

38 Quigley EM, "Motility of the terminal ileum and ileocaecal sphincter in healthy man" 87 : 857-866, 1984

39 Phillips SF, "Motility of the ileocolonic junction" 29 : 390-406, 1988

40 Piche T, "Modulation by colonic fermentation of LES function in humans" 278 : G578-G584, 2000

41 Jiang T, "Modification of colonic fermentation by bifidobacteria and pH in vitro. Impact on lactose metabolism, short- chain fatty acid, and lactate production" 42 : 2370-2377, 1997

42 Uribe A, "Microflora modulates endocrine cells in the gastrointestinal mucosa of the rat" 107 : 1259-1269, 1994

43 Neish AS, "Microbes in gastrointestinal health and disease" 136 : 65-80, 2009

44 Pimentel M, "Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity" 290 : G1089-G1095, 2006

45 Barbara G, "Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome" 132 : 26-37, 2007

46 Thompson JS, "Luminal short-chain fatty acids and postresection intestinal adaptation" 20 : 338-343, 1996

47 Resta-Lenert S, "Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC)" 52 : 988-997, 2003

48 Hasler WL, "Lactulose breath testing, bacterial overgrowth, and IBS: just a lot of hot air" 125 : 1898-1900, 2003

49 Bratten JR, "Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls" 103 : 958-963, 2008

50 Rousseaux C, "Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors" 13 : 35-37, 2007

51 Krishnamurthy S, "Jejunal diverticulosis. A heterogeneous disorder caused by a variety of abnormalities of smooth muscle or myenteric plexus" 85 : 538-547, 1983

52 Si JM, "Intestinal microecology and quality of life in irritable bowel syndrome patients" 10 : 1802-1805, 2004

53 Thompson JS, "Intestinal flora and nutrient absorption after intestinal resection" 1 : 554-560, 1997

54 Gonsalkorale WM, "Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component" 52 : 91-93, 2003

55 Barbara G, "Interactions between commensal bacteria and gut sensorimotor function in health and disease" 100 : 2560-2568, 2005

56 Bradley HK, "Instability in the faecal flora of a patient suffering from food-related irritable bowel syndrome" 23 : 29-32, 1987

57 Kamath PS, "Initiation of motility in canine ileum by short chain fatty acids and inhibition by pharmacological agents" 29 : 941-948, 1988

58 Spiller RC, "Increased rectal mucosal enteroendocrine cells T lymphocytes and increased gut permeability following acute campylobacter enteritis and in post-dysenteric irritable bowel syndrome" 47 : 804-811, 2000

59 Liebregts T, "Immune activation in patients with irritable bowel syndrome" 132 : 913-920, 2007

60 Dinan TG, "Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker" 130 : 304-311, 2006

61 Khan WI, "Gut motor function: immunological control in enteric infection and inflammation" 143 : 389-397, 2005

62 Guarner F, "Gut flora in health and disease" 361 : 512-519, 2003

63 Berseth CL, "Gestational evolution of small intestine motility in preterm and term infants" 115 : 646-651, 1989

64 Berseth CL, "Gastrointestinal motility in the neonate" 23 : 179-190, 1996

65 Törnblom H, "Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome" 123 : 1972-1979, 2002

66 Pimentel M, "Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome" 95 : 3503-3506, 2000

67 Langhorst J, "Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome" 104 : 404-410, 2009

68 Eckburg PB, "Diversity of the human intestinal microbial flora" 308 : 1635-1638, 2005

69 Quigley EM, "Distinctive patterns of interdigestive motility at the canine ileocolonic junction" 87 : 836-844, 1984

70 Brint EK, "Differential expression of toll-like receptors (TLRs) in patients with irritable bowel syndrome" 106 : 329-336, 2011

71 Guilarte M, "Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum" 56 : 203-209, 2007

72 Palmer C, "Development of the human infant intestinal microbiota" 5 : e177-, 2007

73 Kruis W, "Contractile patterns and transit of fluid in canine terminal ileum" 249 (249): G264-G270, 1985

74 Mättö J, "Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome - a longitudinal study in IBS and control subjects" 43 : 213-222, 2005

75 Yu D, "Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS" 60 : 334-340, 2011

76 Ropert A, "Colonic fermentation and proximal gastric tone in humans" 111 : 289-296, 1996

77 Rao AS, "Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis" 139 : 1549-1558, 2010

78 Holmén N, "CD4+ CD25+ regulatory T cells in irritable bowel syndrome patients" 19 : 119-125, 2007

79 Toskes PP, "Bacterial overgrowth of the gastrointestinal tract" 38 : 387-407, 1993

80 Spiegel BM, "Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors" 103 : 2972-2976, 2008

81 Shaw SY, "Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease" 105 : 2687-2692, 2010

82 Schoepfer AM, "Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients" 20 : 1110-1118, 2008

83 Ivison SM, "Anti-flagellin antibodies in irritable bowel syndrome: another attack on our commensals" 20 : 1081-1085, 2008

84 Malinen E, "Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR" 100 : 373-382, 2005

85 Bouhnik Y, "Administration of transgalacto-oligosaccherides increases fecal bifidobacteria and modifies colonic fermentation metabolism in healthy humans" 127 : 444-448, 1997

86 Wine E, "Adherent-invasive Escherichia coli target the epithelial barrier" 1 : 80-84, 2010

87 Chadwick VS, "Activation of the mucosal immune system in irritable bowel syndrome" 122 : 1778-1783, 2002

88 Barbara G, "Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome" 126 : 693-702, 2004

89 Azpiroz F, "Abdominal bloating" 129 : 1060-1078, 2005

90 O’Mahony L, "A randomized, placebo-controlled, double-blind comparison of the probiotic bacteria lactobacillus and bifidobacterium in irritable bowel syndrome (IBS): symptom responses and relationship to cytokine profiles" 128 : 541-551, 2005

91 Sharara AI, "A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence" 101 : 326-333, 2006

92 Codling C, "A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome" 55 : 392-397, 2010

93 Ohman L, "A controlled study of colonic immune activity and beta7+ blood T lymphocytes in patients with irritable bowel syndrome" 3 : 980-986, 2005

94 Collins SM, "A case for an immunological basis for irritable bowel syndrome" 122 : 2078-2080, 2002

95 Quigley EM, "A 51-year-old with irritable bowel syndrome: test or treat for bacterial overgrowth" 5 : 1140-1143, 2007